BioMimetic Therapeutics, Inc.
BioMimetic Therapeutics, Inc. is a biotechnology company, which is specialized in the development and commercialization of innovative products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications. The company's initial focus in orthopedics is the development of Augment Bone Graft as a substitute for autograft in foot and ankle fusions. It also markets a bone graft substitute line of products for orthopedic indications called Augmatrix Biocomposite Bone Graft which are available in multiple forms to suit an array of bone grafting challenges, including fracture repair and general bone void filling procedures. The company was founded by Samuel E. Lynch on April 14, 1999 and is headquartered in Franklin, TN.